Abstract: The present invention relates to modified hMPV F proteins stabilized in the pre-fusion conformation as vaccine candidates.

Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.

Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.

Abstract: The present invention relates to modified metapneumovirus (hMPV) F proteins, stabilized in the pre-fusion conformation. It also relates to immunogenic compositions (vaccines) comprising these proteins for preventing and/or treating human subjects against respiratory tract infections.

Abstract: The present invention relates to methods of rescue and/or propagation of paramyxovirus species, particularly wherein both rescue and propagation are carried out in the same cell type; i.e., without the use of helper cells for viral rescue. The paramyxoviruses produced by the disclosed methods may encompass wild-type viruses, chimeric viruses, recombinant viruses or engineered viral products such as virus like particles (VLP). Viruses and/or viral products produced in the method according to the current invention are suitable for medical or veterinary use in such applications as treating or preventing infectious diseases, particularly avian paramyxovirus and human respiratory virus infections, and cancer treatment.

Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.

Abstract: Described herein are compositions and methods for treating cancers, such as characterized by chronic inflammation or expression of GM1 ganglioside receptors

Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.

Abstract: Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, they disrupt the human CD47-SIRP? interaction, and find use in various therapeutic, preventive or diagnostic methods. The invention includes isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid and nucleotide sequences of the antibodies.

Abstract: An electric heating cable or an electric heating tape having insulating sheaths of polytetrafluoroethylene (PTFE) being arranged in a layered structure is provided. At least one of the PTFE sheaths is protected by at least one adjacent insulating layer of a melt processable fluoropolymer.

Abstract: In a method for manufacturing a winding tape (10) of unsintered polytetrafluoroethylene wherein polytetrafluoroethylene powder is mixed with a lubricating or slip agent, the material is molded into a cylindrical blank (1) and the blank (1) is first extruded as a strand with small outer dimensions and subsequently calendered into the tape (10) in the forming gap (13) of a pair of rolls (8,9). The surface of at least one roll is deformed under compression during calendering of the round rope (6) into the tape.

Abstract: An electric heating cable or an electric heating tape having insulating sheaths of polytetrafluoroethylene (PTFE) being arranged in a layered structure is provided. At least one of the PTFE sheaths is protected against shock by at least one adjacent insulating layer of a melt processable fluoropolymer.

Abstract: In a method for manufacturing a winding tape (10) of unsintered polytetrafluoroethylene wherein polytetrafluoroethylene powder is mixed with a lubricating or slip agent, the material is molded into a cylindrical blank (1) and the blank (1) is first extruded as a strand with small outer dimensions and subsequently calendered into the tape (10) in the forming gap (13) of a pair of rolls (8,9). The surface of at least one roll is deformed under compression during calendering of the round rope (6) into the tape.

Abstract: Extrudable halogen-free mixture comprising 95-5 weight-% polyetherimide polymer with an elastic modulus greater than 2000 MPa and 5-95 weight-% flexible siloxane-polyetherimide copolymer with an elastic modulus of less than 2000 MPa. Electrical cable or wiring insulated with the extrudable halogen-free mixture comprising 60-90 weight-% of a polyetherimide polymer with an elastic modulus greater than 2000 MPa and 40-10 weight-% of a flexible siloxane-polyetherimide copolymer with an elastic modulus of less than 1000 MPa. Electrical or optical cable or tubing sheathed with the extrudable halogen-free mixture comprising 40-10 weight-% of a polyetherimide polymer with an elastic modulus greater than 2000 MPa and 60-90 weight-% of a flexible siloxane-polyetherimide copolymer with an elastic modulus of less than 1000 MPa.

Abstract: Recesses or openings (4) are arranged in a wall of an elongated tubular covering (3) made of resinous plastics that are resistant to temperature stresses and/or aggressive media; these openings are covered from the outside by a microporous layer (5) made of a fluoropolymer that is resistant to high temperatures.